Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ENSEMBLE

- PMLiVE

US demand for COVID-19 antibody treatments rising fast

With the ‘fourth wave’ of COVID-19 in the US, Regeneron and GSK report high demand for their monoclonal antibody treatments

- PMLiVE

Pfizer/BioNTech file for FDA approval for COVID-19 booster jab

New data shows third dose boosts antibodies by more than three times

- PMLiVE

Protection against COVID-19 reduces over time in fully vaccinated, according to new real-world study

The Zoe COVID-19 Study shows protection could fall by up to 14%

- PMLiVE

FDA’s approval of Pfizer/BioNTech’s COVID-19 vaccine “is a milestone” says acting FDA commissioner Janet Woodcock

After more than a billion doses have been given worldwide, Comirnaty is now officially approved for people aged 16 and over in the US

- PMLiVE

AZ to seek approval for “long-acting” COVID-19 antibodies

AZD7442 significantly reduced the risk of developing symptomatic COVID-19 in phase 3 trial and is a one-dose treatment that can be given via an intramuscular injection

regeneron headquarters

UK approves Regeneron’s COVID-19 antibody cocktail

Ronapreve is the first monoclonal antibody therapy against COVID-19 approved in Europe

- PMLiVE

COVID-19 vaccine protection wanes over time, backing up the need for boosters

While both Pfizer/BioNTech and AstraZeneca’s vaccines offer good protection, a new UK study shows the protection reduces over time and the UK's booster campaign is likely to begin in September

- PMLiVE

US health leaders greenlight COVID-19 booster shots for “all Americans”

In light of “very clear” evidence that protection from COVID-19 vaccines declines over time, the US will start offering boosters shots from September

- PMLiVE

US health leaders greenlight COVID-19 booster shots for “all Americans”

In light of “very clear” evidence that protection from COVID-19 vaccines declines over time, the US will start offering boosters shots from September

- PMLiVE

WHO to test three more potential COVID-19 treatments

The expanded Solidarity PLUS trial will test artesunate, imatinib and infliximab on hospitalised COVID-19 patients in a trial that will involve thousands of researchers in 52 countries

- PMLiVE

Pfizer/BioNTech submit data for COVID-19 booster shots

Booster shots are expected to be approved quickly in the US, as cases of delta variant surge

- PMLiVE

First oral antiviral drug for COVID-19 reviewed by Health Canada

Early phase 2/3 data including early safety, quality and efficacy data for Merck’s molnupiravir will be reviewed by the regulator while the study is still underway

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links